secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001558370-23-014482
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q2 net loss $7.7M; Phase 1 trial submission for GT-02287
--------------------------------------------------------------------------

- Net loss $7.7M ($0.62/share) vs $5.1M ($0.43) in Q2 2022, driven by higher R&D and G&A costs.
- R&D expenses $4.0M, up $1.4M YoY due to preclinical studies and manufacturing for GBA1 Parkinson's program.
- Cash and securities $16.2M; company expects to fund operations into Q3 2024.
- Submitted HREC dossier to initiate Phase 1 trial of GT-02287 in Australia in H2 2023.
- Late-breaking abstract accepted for presentation at International Congress of Parkinson's Disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023014482/0001558370-23-014482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023014482/ganx-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer